XX (a PD-1 Inhibitor), Stereotactic Body Radiotherapy and Granulocyte-Macrophage Colony Stimulating Factor as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer: Safety Run-In Results of a Prospective, Multicenter, Phase II Trial
第一作者单位：[1]Fudan Univ, Dept Radiat Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Ni J.,Wu L.,Ai X.,et al.XX (a PD-1 Inhibitor), Stereotactic Body Radiotherapy and Granulocyte-Macrophage Colony Stimulating Factor as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer: Safety Run-In Results of a Prospective, Multicenter, Phase II Trial[J].INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS.2021,111(3):E422-E422.
APA：
Ni, J.,Wu, L.,Ai, X.,Dong, X.,Chu, Q....&Zhu, Z..(2021).XX (a PD-1 Inhibitor), Stereotactic Body Radiotherapy and Granulocyte-Macrophage Colony Stimulating Factor as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer: Safety Run-In Results of a Prospective, Multicenter, Phase II Trial.INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS,111,(3)
MLA：
Ni, J.,et al."XX (a PD-1 Inhibitor), Stereotactic Body Radiotherapy and Granulocyte-Macrophage Colony Stimulating Factor as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer: Safety Run-In Results of a Prospective, Multicenter, Phase II Trial".INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 111..3(2021):E422-E422
医学